Low hand grip strength (HGS) is associated with health conditions, but the value of this measure is unclear for diverse populations. Researchers from Verily and Duke Clinical Research Institute analyzed data from participants of the Project Baseline Health Study to better understand the association between HGS and various characteristics of health in a community-dwelling population. The results, published in Nature Portfolio's Scientific Reports, show that HGS can be a useful indicator of a variety of clinical characteristics for specific demographic groups.
It is estimated that as many as 1 million people in the U.S. live with Parkinson’s disease (PD) and nearly 90,000 new cases are diagnosed yearly.* There is no cure. In support of accelerating research for treatments and cures, we are proud to collaborate with partners using Verily’s Workbench technology to increase access to high-quality Parkinson’s disease data. Since 2018, we have worked with the Accelerating Medicines Partnership® Parkinson’s disease (AMP PD) program. Verily led the development of the AMP PD Knowledge Portal, which houses and enables the sharing of de-identified data and findings among all AMP PD partners who are working to identify the most promising biomarkers for use in clinical trials for new PD treatments. Learn more about AMP PD: https://bit.ly/3JDQpek In the last year we announced a partnership with The Michael J. Fox Foundation for Parkinson's Research. They will use Verily Viewpoint Workbench to provide a collaborative and secure data environment for programs focused on providing Parkinson’s data to researchers, including Global Parkinson’s Genetics Program (GP2) and the Aligning Science Across Parkinson’s | ASAP initiatives. Learn more: https://bit.ly/3QiyWfp hashtag#ParkinsonsAwareness hashtag#ParkinsonsDisease hashtag#ClinicalResearch hashtag#FindACure * Parkinson's Foundation
In an interview with TCTMD, Sooyoon Shin, our Digital Biomarkers Clinical Science Lead, shared the results of a Verily-led study showing the potential for walking measures captured by the Verily Study Watch to help identify patients at risk for heart failure. “While research on wearables’ role in advancing cardiometabolic health has increased exponentially in recent years, our study is unique in that it looked at subclinical heart failure and did so in a real-life setting with a diverse population, and with an eye toward patient-reported outcomes,” said Sooyoon. Read more about the study, which was recently published in the Journal of Cardiac Failure.
One of the most challenging global public health problems is the spread of mosquito-borne diseases. Watch to learn how Verily Sightline Debug is used to fight these diseases by raising and releasing “good” mosquitoes. https://bit.ly/3xRcljO
Alphabet, Verily's parent company, is listed in LinkedIn Top Companies 2024: The 50 best large workplaces to grow your career in the U.S.. Top U.S. locations: San Francisco Bay Area; New York City; Seattle Most notable skills: Mobile Application Development, Artificial Intelligence, Signal Processing Most common job titles: Software Engineer, Program Manager, Product Manager Largest job functions: Engineering, Information Technology, Program and Product Management Flex work availability: 5.1% remote How they encourage employee development: Google’s “Googler-to-Googler” peer learning and coaching platform allows employees to either coach or learn from their colleagues in different fields across the company.
At MM+M Transform earlier this month, our CMO Alix Hart spoke about techno-empathy and the ways Verily is using technology to prioritize the human experience in healthcare. Watch the recording: https://bit.ly/4d4twOH
Andrew Trister, MD PhD, Verily Chief Medical and Science Officer, discussed with Medtech Insight the opportunity to bring together data from a wide range of sources, including wearables, EHRs and social determinants of health to personalize how we manage health. He highlighted Verily Onduo as a solution for advancing precision health for chronic conditions. Read more: https://bit.ly/3UnIXuk
If we can better understand mental health conditions across time and in a real-world setting, we can inform precise treatments that support patients earlier. Verily’s Andrew Trister, MD PhD and Otsuka Pharmaceutical Companies (U.S.)’s John Kraus shared details on the newly launched longitudinal registry study, ‘My Mental Health Journey,’ which aims to do just that. Read more in Behavioral Health Business: https://bit.ly/3U0uxyU
A huge thank you to all the lab professionals here at Verily! Your behind-the-scenes work and dedication are vital to realizing the promise of precision health. Happy Lab Week!
We welcome our new Chief Revenue Officer Bharat Rajagopal on his first day at Verily! Bharat, who was previously at Microsoft, will be responsible for the strategy and execution of all commercial revenue generating activities to advance precision health. In his own words: “With the recent advances in AI, we have a generational opportunity to discover therapies never imagined before. I’m thrilled to continue my mission at Verily by partnering with organizations across the ecosystem to deliver new data, AI, and technology solutions that accelerate evidence generation and advance precision health.” Learn more: https://bit.ly/3xCtLjU
